Wolfler Andrea, Raimondi Gianfranco, Pagan de Paganis Cecilia, Zoia Elena
Division of Anesthesia and Intensive Care, Department of Pediatrics, Children's Hospital Vittore Buzzi, ASST FBF Sacco, Milan, Italy -
Division of Anesthesia and Intensive Care, Department of Pediatrics, Children's Hospital Vittore Buzzi, ASST FBF Sacco, Milan, Italy.
Minerva Pediatr. 2018 Dec;70(6):612-622. doi: 10.23736/S0026-4946.18.05358-6. Epub 2018 Oct 18.
Bronchiolitis is one of the most frequent reasons for Pediatric Intensive Care Unit (PICU) admission in children less than 1 year of age. It causes a wide spectrum of clinical scenarios from mild to severe respiratory failure and supportive therapy range from high flow nasal cannula (HFNC) to nonconventional ventilation and extra corporeal membrane oxygenation (ECMO) in the most severe forms. Aim of this article is to review the available ventilation mode in children with bronchiolitis and the scientific evidence. The main medical databases were explored to search for clinical trials that address management strategies for respiratory support of infants with respiratory syncytial virus (RSV) infection. HFNC use is increasing and it seems to be useful as first line therapy in the emergency room and in the pediatric ward to prevent PICU admission but it is not clear yet if it is equivalent to noninvasive ventilation (NIV). NIV use in bronchiolitis is well established, mainly in continuous positive airway pressure mode in moderate and severe bronchiolitis. A mild evidence towards use of NIV to prevent endotracheal intubation is raising from few studies. Finally, for patients who failed a NIV trial, endotracheal intubation should be considered as the best option to support ventilation with conventional, nonconventional mode and ECMO in the most severe acute respiratory distress syndromes. There is a lack of quality studies for the use of any of the proposed ventilatory support in infants with bronchiolitis, especially in the severe forms. Nevertheless, in the last two decades daily use of noninvasive positive pressure supports have reached a large consensus based on clinical judgement and weak published evidence. We need specific and clear guidelines on which is the optimal management of these patients, and more robust randomized clinical trials to best evaluate timing and efficacy of HFNC and NIV use.
细支气管炎是1岁以下儿童入住儿科重症监护病房(PICU)最常见的原因之一。它会引发从轻度到重度呼吸衰竭的一系列临床情况,支持性治疗范围从高流量鼻导管吸氧(HFNC)到最严重形式下的非常规通气和体外膜肺氧合(ECMO)。本文旨在综述细支气管炎患儿可用的通气模式及科学证据。我们检索了主要医学数据库,以查找针对呼吸道合胞病毒(RSV)感染婴儿呼吸支持管理策略的临床试验。HFNC的使用正在增加,它似乎可作为急诊室和儿科病房预防PICU入住的一线治疗方法,但它是否等同于无创通气(NIV)尚不清楚。NIV在细支气管炎中的应用已得到充分确立,主要用于中重度细支气管炎的持续气道正压通气模式。少数研究对使用NIV预防气管插管提供了一些微弱的证据。最后,对于NIV试验失败的患者,气管插管应被视为在最严重的急性呼吸窘迫综合征中采用常规、非常规模式和ECMO支持通气的最佳选择。对于细支气管炎婴儿使用任何一种提议的通气支持,都缺乏高质量的研究,尤其是在严重形式的细支气管炎中。然而,在过去二十年中,基于临床判断和薄弱的已发表证据,无创正压支持的日常使用已达成广泛共识。我们需要关于这些患者最佳管理的具体明确指南,以及更有力的随机临床试验,以更好地评估HFNC和NIV使用的时机和疗效。